224 related articles for article (PubMed ID: 19445902)
41. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
42. Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.
Salyakina D; Roy S; Wang W; Oliva M; Akhouri R; Sotto I; Mulas N; Solano R; Fernández JR; Sanchez S; Shamshad U; Perlyn C; McCafferty-Fernandez J
Mol Genet Genomic Med; 2019 Sep; 7(9):e922. PubMed ID: 31389673
[TBL] [Abstract][Full Text] [Related]
43. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
[TBL] [Abstract][Full Text] [Related]
44. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
Hicks JK; Swen JJ; Gaedigk A
Curr Drug Metab; 2014 Feb; 15(2):218-32. PubMed ID: 24524666
[TBL] [Abstract][Full Text] [Related]
45. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
Sauer JM; Ponsler GD; Mattiuz EL; Long AJ; Witcher JW; Thomasson HR; Desante KA
Drug Metab Dispos; 2003 Jan; 31(1):98-107. PubMed ID: 12485958
[TBL] [Abstract][Full Text] [Related]
46. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
47. Polymorphic hydroxylation of perhexiline in vitro.
Sørensen LB; Sørensen RN; Miners JO; Somogyi AA; Grgurinovich N; Birkett DJ
Br J Clin Pharmacol; 2003 Jun; 55(6):635-8. PubMed ID: 12814462
[TBL] [Abstract][Full Text] [Related]
48. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
49. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.
Li J; Kim S; Sha X; Wiegand R; Wu J; LoRusso P
Clin Cancer Res; 2014 Aug; 20(15):3931-44. PubMed ID: 24947923
[TBL] [Abstract][Full Text] [Related]
50. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
51. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Caudle KE; Sangkuhl K; Whirl-Carrillo M; Swen JJ; Haidar CE; Klein TE; Gammal RS; Relling MV; Scott SA; Hertz DL; Guchelaar HJ; Gaedigk A
Clin Transl Sci; 2020 Jan; 13(1):116-124. PubMed ID: 31647186
[TBL] [Abstract][Full Text] [Related]
52. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
Lymperopoulos A; McCrink KA; Brill A
Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
[TBL] [Abstract][Full Text] [Related]
53. Potential role of CYP2D6 in the central nervous system.
Cheng J; Zhen Y; Miksys S; Beyoğlu D; Krausz KW; Tyndale RF; Yu A; Idle JR; Gonzalez FJ
Xenobiotica; 2013 Nov; 43(11):973-84. PubMed ID: 23614566
[TBL] [Abstract][Full Text] [Related]
54. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
de Leon J; Susce MT; Pan RM; Fairchild M; Koch WH; Wedlund PJ
J Clin Psychiatry; 2005 Jan; 66(1):15-27. PubMed ID: 15669884
[TBL] [Abstract][Full Text] [Related]
55. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
Felmlee MA; Lon HK; Gonzalez FJ; Yu AM
Drug Metab Dispos; 2008 Feb; 36(2):435-41. PubMed ID: 18048490
[TBL] [Abstract][Full Text] [Related]
56. Cytochrome P
Dhuya M; Pal MM; Hazra A; Chatterjee S; Gogtay N
Indian J Pharmacol; 2020; 52(3):189-195. PubMed ID: 32874001
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenetics of classical and new antipsychotic drugs.
Otani K; Aoshima T
Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
[TBL] [Abstract][Full Text] [Related]
58. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
[TBL] [Abstract][Full Text] [Related]
59. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Drug Metab Dispos; 2004 Apr; 32(4):379-81. PubMed ID: 15039289
[TBL] [Abstract][Full Text] [Related]
60. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
